CellaVision has previously met the Taiwanese Quality System Documentation requirements (QSD), which, in combination with the product registration will allow for SanTung Instruments to begin marketing the CellaVision(TM) DM96 in Taiwan.
"Taiwan represents a significant market, which is why it is particularly important to work with a partner that has both extensive experience of the laboratory market as well as good knowledge of our applications," comments Yvonne Mårtensson, CEO of CellaVision. "The population of Taiwan is the size of the Nordic market and the country has a purchasing power of the EU. The first order is of an instrument that will be used to generate sales, as most clients choose to evaluate instruments in their laboratories before deciding to purchase."
CellaVision's products were presented at the Congress of Taiwan Society of Laboratory Medicine exhibition in Taipei between the 10th and 11th of November.
The product registration was issued by the Taiwanese Department of Health, DOH.
For more information, please contact:
Yvonne Mårtensson, CEO, CellaVision AB
Phone: +46 286 44 00. E-mail: yvonne.martensson@cellavision.com
About SanTung Instruments Co
For more information, visit www.san-tung.com.tw.
About CellaVision
CellaVision AB develops, markets, and sells market-leading systems for performing automatic identification of white blood cells, characterization of red blood cell morphology, and software for education and competency assessment. The company's core competencies are in advanced imaging analysis, artificial intelligence, and automated microscopy, resulting in the development of software and hardware for automatic image analysis of cells and cell changes, with applications in healthcare.
The company headquarters are in Lund, Sweden and has subsidiaries in Jupiter, FL, USA, and Toronto, ON, Canada. For more information, visit www.cellavision.com.
CellaVision's share is listed on First North at the OMX Stockholm Stock Exchange. The company's Certified Advisor is Remium AB.